Ratings by Roth/MKM (Elemer Piros)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 11/7/2022 | Clene, Inc. | CLNN | Maintain | Buy (N/A) |
|
Details | ||
| 10/20/2022 | Axcella Health Inc. | AXLA | Maintain | Buy (N/A) |
|
Details | ||
| 9/19/2022 | MindMed | MNMD | Maintain | Buy (N/A) |
|
Details | ||
| 8/11/2022 | Monopar Therapeutics | MNPR | Maintain | Buy (N/A) |
|
Details | ||
| 8/9/2022 | Apellis Pharmaceuticals | APLS | Maintain | Sell (N/A) |
|
Details | ||
| 6/30/2022 | Field Trip Health Ltd. | FTRP | Maintain | Buy (N/A) |
|
Details | ||
| 6/16/2022 | GH Research PLC | GHRS | New Coverage | Buy (N/A) |
10.42 (19.18) |
84.07% | Details | |
| 5/11/2022 | Lumos Pharma | LUMO | Maintain | Buy (N/A) |
|
Details | ||
| 5/11/2022 | Clene, Inc. | CLNN | Maintain | Buy (N/A) |
|
Details | ||
| 5/4/2022 | MindMed | MNMD | New Coverage | Buy (N/A) |
12.60 (15.02) |
19.21% | Details | |
| 4/13/2022 | Apellis Pharmaceuticals | APLS | Downgrade | Sell (Neutral) |
52.39 (19.38) |
-63.01% | Details | |
| 1/4/2022 | Unity Biotechnology Inc | UBX | Upgrade | Buy (Neutral) |
1.75 (0.20) |
-88.57% | Details | |
| 12/1/2021 | BioRestorative Therapies Inc. | BRTX | New Coverage | Buy (N/A) |
6.29 (1.58) |
-74.88% | Details | |
| 11/29/2021 | Apellis Pharmaceuticals | APLS | Downgrade | Neutral (Buy) |
43.38 (52.39) |
20.77% | Details | |
| 11/16/2021 | Cybin Inc. | CYBN | Maintain | Buy (N/A) |
|
Details | ||
| 11/11/2021 | atai Life Sciences N.V | ATAI | New Coverage | Buy (N/A) |
15.37 (7.35) |
-52.18% | Details | |
| 11/9/2021 | Compass Pathways | CMPS | Maintain | Buy (N/A) |
|
Details | ||
| 8/9/2021 | Unicycive Therapeutics | UNCY | New Coverage | Buy (N/A) |
2.65 (3.58) |
35.09% | Details | |
| 6/29/2021 | DiaMedica Therapeutics Inc. | DMAC | Maintain | Buy (N/A) |
|
Details | ||
| 5/13/2021 | Compass Pathways | CMPS | Maintain | Buy (N/A) |
|
Details | ||
| 5/6/2021 | Global Blood Therapeutics | GBT | Maintain | Buy (N/A) |
|
Details | ||
| 4/28/2021 | Cybin Inc. | CLXPF | New Coverage | Buy (N/A) |
1.48 (3.02) |
104.05% | Details | |
| 4/1/2021 | Compass Pathways | CMPS | New Coverage | Buy (N/A) |
35.30 (11.05) |
-68.7% | Details | |
| 3/15/2021 | Corbus Pharmaceuticals | CRBP | Maintain | Neutral (N/A) |
|
Details | ||
| 2/17/2021 | DiaMedica Therapeutics Inc. | DMAC | New Coverage | Buy (N/A) |
9.40 (8.74) |
-7.02% | Details | |
| 2/3/2021 | Clene, Inc. | CLNN | New Coverage | Buy (N/A) |
6.55 (3.84) |
-41.37% | Details | |
| 1/28/2021 | Monopar Therapeutics | MNPR | New Coverage | Buy (N/A) |
6.81 (2.62) |
-61.53% | Details | |
| 12/23/2020 | Arcturus Therapeutics | ARCT | Downgrade | Sell (Buy) |
118.46 (9.91) |
-91.63% | Details | |
| 12/14/2020 | Apellis Pharmaceuticals | APLS | Maintain | Buy (N/A) |
|
Details | ||
| 12/1/2020 | Hepion Pharma | HEPA | Maintain | Buy (N/A) |
|
Details | ||
| 9/17/2020 | CohBar | CWBR | New Coverage | Buy (N/A) |
1.02 (0.41) |
-59.8% | Details | |
| 9/8/2020 | Corbus Pharmaceuticals | CRBP | Downgrade | Neutral (Buy) |
9.25 (3.99) |
-56.86% | Details | |
| 8/17/2020 | Unity Biotechnology Inc | UBX | Downgrade | Neutral (Buy) |
12.43 (1.75) |
-85.92% | Details | |
| 8/17/2020 | Lumos Pharma | LUMO | New Coverage | Buy (N/A) |
15.05 (4.34) |
-71.16% | Details | |
| 7/30/2020 | Arcturus Therapeutics | ARCT | New Coverage | Buy (N/A) |
55.60 (9.91) |
-82.18% | Details | |
| 7/28/2020 | Unity Biotechnology Inc | UBX | New Coverage | Buy (N/A) |
8.24 (12.43) |
50.85% | Details | |
| 7/20/2020 | Apellis Pharmaceuticals | APLS | New Coverage | Buy (N/A) |
32.54 (41.03) |
26.09% | Details | |
| 7/20/2020 | Global Blood Therapeutics | GBT | New Coverage | Buy (N/A) |
74.49 (68.49) |
-8.05% | Details | |
| 7/20/2020 | Hepion Pharma | HEPA | New Coverage | Buy (N/A) |
3.70 (0.32) |
-91.35% | Details | |
| 7/7/2020 | Corbus Pharmaceuticals | CRBP | New Coverage | Buy (N/A) |
7.91 (3.99) |
-49.56% | Details |
